Literature DB >> 8592710

Crystallization of intact monoclonal antibodies.

L J Harris1, E Skaletsky, A McPherson.   

Abstract

Attempts were made to crystallize four monoclonal antibodies, one IgG2a kappa and three IgG1 kappa. Using a PEG 3350 screen combined with detergents, and developed from our experiments with an IgG2a kappa antibody specific for canine lymphoma cells, crystals have now been obtained of two of these four immunoglobulins, an antiphenytoin and an antiphenobarbital antibody. A complex between the antiphenobarbital antibody and its drug antigen crystallized as well. The antibody for phenytoin has, to this point, produced only clustered microcrystals, marginally suitable for X-ray analysis. Single crystals of the IgG1 kappa antibody against phenobarbital, however, were characterized by X-ray diffraction to be primitive monoclinic, with unit cell dimensions a = 67 A, b = 193 A, c = 74 A, and beta = 110 degrees. These crystals have an entire IgG1 kappa molecule as the asymmetric unit and they diffract to at least 3.2 A resolution.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592710     DOI: 10.1002/prot.340230218

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  11 in total

1.  Freezing immunoglobulins to see them move.

Authors:  L Bongini; D Fanelli; F Piazza; P De Los Rios; S Sandin; U Skoglund
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-13       Impact factor: 11.205

2.  Phase behavior of an intact monoclonal antibody.

Authors:  Tangir Ahamed; Beatriz N A Esteban; Marcel Ottens; Gijs W K van Dedem; Luuk A M van der Wielen; Marc A T Bisschops; Albert Lee; Christine Pham; Jörg Thömmes
Journal:  Biophys J       Date:  2007-04-20       Impact factor: 4.033

Review 3.  Optimization of crystallization conditions for biological macromolecules.

Authors:  Alexander McPherson; Bob Cudney
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-10-31       Impact factor: 1.056

4.  The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen.

Authors:  Ivan Correia; Joyce Sung; Randall Burton; Clarissa G Jakob; Bridget Carragher; Tariq Ghayur; Czeslaw Radziejewski
Journal:  MAbs       Date:  2013-04-09       Impact factor: 5.857

5.  Molecular basis for passive immunotherapy of Alzheimer's disease.

Authors:  Anna S Gardberg; Lezlee T Dice; Susan Ou; Rebecca L Rich; Elizabeth Helmbrecht; Jan Ko; Ronald Wetzel; David G Myszka; Paul H Patterson; Chris Dealwis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-25       Impact factor: 11.205

6.  Solution structure of deglycosylated human IgG1 shows the role of CH2 glycans in its conformation.

Authors:  Valentina A Spiteri; James Doutch; Robert P Rambo; Jayesh Gor; Paul A Dalby; Stephen J Perkins
Journal:  Biophys J       Date:  2021-03-04       Impact factor: 4.033

7.  Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.

Authors:  Gabriela A N Crespi; Stefan J Hermans; Michael W Parker; Luke A Miles
Journal:  Sci Rep       Date:  2015-04-16       Impact factor: 4.379

8.  Segregation of PIP2 and PIP3 into distinct nanoscale regions within the plasma membrane.

Authors:  Jie Wang; David A Richards
Journal:  Biol Open       Date:  2012-07-10       Impact factor: 2.422

9.  Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee.

Authors:  Nathan I Nicely; Kevin Wiehe; Thomas B Kepler; Frederick H Jaeger; S Moses Dennison; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Merlin L Robb; Robert J O'Connell; Nelson L Michael; Jerome H Kim; Hua-Xin Liao; S Munir Alam; Kwan-Ki Hwang; Mattia Bonsignori; Barton F Haynes
Journal:  EBioMedicine       Date:  2015-06-20       Impact factor: 8.143

Review 10.  Crystallization screening: the influence of history on current practice.

Authors:  Joseph R Luft; Janet Newman; Edward H Snell
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-06-27       Impact factor: 1.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.